Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EYPTNASDAQ:LABNASDAQ:SEERNYSE:SENS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYPTEyepoint Pharmaceuticals$9.18+10.9%$7.07$3.91▼$13.99$569.76M1.61812,805 shs848,290 shsLABStandard BioTools$1.22-0.8%$1.10$0.92▼$2.41$467.18M1.52.13 million shs3.72 million shsSEERSeer$1.97$2.03$1.56▼$2.63$115.97M1.54324,143 shs132,434 shsSENSSenseonics$0.50+1.2%$0.58$0.25▼$1.40$328.61M0.966.94 million shs19.30 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYPTEyepoint Pharmaceuticals+10.87%+4.20%+61.62%+51.49%+7.75%LABStandard BioTools-0.81%+19.61%+32.38%+2.52%-32.22%SEERSeer0.00%+0.51%-6.19%+8.24%+13.87%SENSSenseonics+1.21%+0.54%-0.48%-30.24%+37.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEYPTEyepoint Pharmaceuticals2.0634 of 5 stars3.52.00.00.02.41.70.0LABStandard BioTools2.9178 of 5 stars3.32.00.00.02.03.31.3SEERSeer2.5725 of 5 stars3.03.00.00.01.73.30.6SENSSenseonics2.0833 of 5 stars3.83.00.00.01.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEYPTEyepoint Pharmaceuticals 3.00Buy$25.67179.59% UpsideLABStandard BioTools 2.50Moderate Buy$2.50104.92% UpsideSEERSeer 2.00Hold$3.0052.28% UpsideSENSSenseonics 3.50Strong Buy$1.55208.58% UpsideCurrent Analyst Ratings BreakdownLatest SEER, LAB, SENS, and EYPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025EYPTEyepoint PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$28.006/2/2025SENSSenseonicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy$1.105/29/2025EYPTEyepoint PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.005/16/2025EYPTEyepoint PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.005/8/2025EYPTEyepoint PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $27.004/10/2025SENSSenseonicsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$2.004/9/2025SENSSenseonicsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEYPTEyepoint Pharmaceuticals$43.27M14.60N/AN/A$4.93 per share1.86LABStandard BioTools$169.69M2.73N/AN/A$1.27 per share0.96SEERSeer$14.17M8.18N/AN/A$5.54 per share0.36SENSSenseonics$23.68M13.88N/AN/A$0.07 per share7.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEYPTEyepoint Pharmaceuticals-$130.87M-$2.41N/AN/AN/A-261.91%-54.27%-41.75%8/6/2025 (Estimated)LABStandard BioTools-$138.88M-$0.35N/AN/AN/A-78.24%-22.44%-16.74%7/30/2025 (Estimated)SEERSeer-$86.60M-$1.41N/AN/AN/A-560.90%-24.69%-22.13%8/6/2025 (Estimated)SENSSenseonics-$60.39M-$0.11N/AN/AN/A-362.30%-842.25%-67.99%N/ALatest SEER, LAB, SENS, and EYPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SEERSeer-$0.37-$0.34+$0.03-$0.34$3.25 million$4.21 million5/7/2025Q1 2025EYPTEyepoint Pharmaceuticals-$0.65-$0.65N/A-$0.65$8.84 million$24.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEYPTEyepoint PharmaceuticalsN/AN/AN/AN/AN/ALABStandard BioToolsN/AN/AN/AN/AN/ASEERSeerN/AN/AN/AN/AN/ASENSSenseonicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEYPTEyepoint PharmaceuticalsN/A7.857.79LABStandard BioToolsN/A6.125.37SEERSeerN/A19.3418.81SENSSenseonics59.172.472.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEYPTEyepoint Pharmaceuticals99.41%LABStandard BioTools53.74%SEERSeer75.20%SENSSenseonics12.36%Insider OwnershipCompanyInsider OwnershipEYPTEyepoint Pharmaceuticals4.46%LABStandard BioTools23.16%SEERSeer11.28%SENSSenseonics4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEYPTEyepoint Pharmaceuticals12068.81 million65.74 millionOptionableLABStandard BioTools620379.82 million291.86 millionOptionableSEERSeer16058.87 million52.23 millionOptionableSENSSenseonics90654.22 million573.90 millionN/ASEER, LAB, SENS, and EYPT HeadlinesRecent News About These CompaniesADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensorsJune 24 at 2:52 PM | medtechdive.comSenseonics lays out hopes for next-gen CGM commercial timelinesJune 24 at 2:52 PM | drugdeliverybusiness.comHere's Why Senseonics (SENS) is Poised for a Turnaround After Losing 5.7% in 4 WeeksJune 18, 2025 | zacks.comMillennium Management LLC Has $569,000 Stock Position in Senseonics Holdings, Inc. (NYSE:SENS)June 9, 2025 | marketbeat.comSenseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with DiabetesJune 4, 2025 | globenewswire.comAnalysts Offer Predictions for Senseonics FY2025 EarningsJune 4, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Senseonics Q2 Earnings?June 3, 2025 | marketbeat.comSenseonics (NYSE:SENS) Given Buy Rating at HC WainwrightJune 2, 2025 | marketbeat.comSenseonics Holdings, Inc. Secures $57.5 Million in Public Offering and $20.3 Million from Private Placement with Abbott LaboratoriesMay 21, 2025 | quiverquant.comSenseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private PlacementMay 21, 2025 | globenewswire.comRevisiting Senseonics After 4 Years: Still A Big Investment OpportunityMay 21, 2025 | seekingalpha.comSenseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private PlacementMay 15, 2025 | globenewswire.comSenseonics opens $50M public offering, $25M private placement with AbbottMay 15, 2025 | drugdeliverybusiness.comSenseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private PlacementMay 15, 2025 | globenewswire.comSenseonics Holdings, Inc. (AMEX:SENS) Q1 2025 Earnings Call TranscriptMay 9, 2025 | msn.comSenseonics Holdings, Inc. Reports First Quarter Financial ResultsMay 9, 2025 | finance.yahoo.comSenseonics posts Q2 sales beat, submits 365-day CGM for CE markMay 9, 2025 | drugdeliverybusiness.comSenseonics targets $34M-$38M revenue in 2025 with Eversense 365 expansionMay 9, 2025 | msn.comSenseonics Holdings, Inc. (SENS) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comSenseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comSequel Med Tech and Senseonics Partner to Launch twiist™ AID System Compatible with Eversense® 365 CGMApril 30, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines4 Buy-and-Hold-Forever Stocks Available at a BargainBy Nathan Reiff | June 16, 2025View 4 Buy-and-Hold-Forever Stocks Available at a BargainGitLab: Buy It Low While You Still Can—Higher Prices Are ComingBy Thomas Hughes | June 11, 2025View GitLab: Buy It Low While You Still Can—Higher Prices Are ComingRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?5 Stocks Set to Soar This SummerBy Ryan Hasson | June 2, 2025View 5 Stocks Set to Soar This SummerOuster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesBy Leo Miller | June 14, 2025View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesSEER, LAB, SENS, and EYPT Company DescriptionsEyepoint Pharmaceuticals NASDAQ:EYPT$9.18 +0.90 (+10.87%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$9.06 -0.12 (-1.25%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Standard BioTools NASDAQ:LAB$1.22 -0.01 (-0.81%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.24 +0.02 (+1.23%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.Seer NASDAQ:SEER$1.97 0.00 (0.00%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.98 +0.01 (+0.51%) As of 06/24/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.Senseonics NYSE:SENS$0.50 +0.01 (+1.21%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$0.51 +0.00 (+0.74%) As of 04:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
